Dr Reddy, Q2

Dr Reddy's Labs shares in focus after Q2 profit falls 15% YoY. What should investors do?
Dr. Reddy's Labs reported a 15% decline in Q2 net profit, despite a 17% rise in revenue driven by global generics. While analysts acknowledge the strong revenue momentum, opinions are divided on the stock's future prospects,
Dr Reddy’s Laboratories Q2 Results: Net profit drops 9.5% to ₹1,342 crore on acquisition cost, revenue up 16.5% YoY
The drugmaker’s total revenue from operations in the second quarter of current fiscal rose 16.5 per cent to ₹8,016 crore.
Dr Reddy's Labs Q2 Preview: Profits may decline 7%, revenues to rise 12%
Dr Reddy's Lab’s average revenue will potentially increase 12 per cent Y-o-Y to Rs 7,734 crore as against Rs 6,902 crore in Q2FY24. On a quarterly basis, the revenues may rise by 0.4 per cent. The pharma company registered revenues of Rs 7,696 crore in the June quarter of FY25.
India's Dr Reddy's Q2 profit drops on acquisition cost, impairment charge
By Rishika Sadam and Kashish Tandon HYDERABAD/BENGALURU (Reuters) -Indian generic drugmaker Dr Reddy's Laboratories' second-quarter profit was hit by one-time charges related to its joint venture with Nestle India and Nicotinell acquisition,
Dr Reddy's Q2 net profit falls 9.3 pc to Rs 1,341.5 cr; revenue up 16.5 pc
Pharma major Dr Reddy’s Laboratories (DRL) on Tuesday reported a 9.35 per cent decline in its consolidated net profit to Rs 1,341.5 crore for the second quarter ended September 2024. DRL had posted a net profit of Rs 1,
Q2 results today: Titan, Mazagon, and Dr Reddy's among 63 to post earnings
GAIL India, Oil India, Merger Paints, Mankind Pharma, and Saregama will be releasing their earnings report for the July-September quarter on Nov 5
India's Dr Reddy's misses Q2 profit view on weak pricing in North America
(Reuters) -Indian generic drugmaker Dr Reddy's Laboratories reported a second-quarter profit that missed analysts' expectations on Tuesday, weighed down by pricing pressure in a competitive North American market,
ndtvprofit32m
Dr. Reddy's Q2 Results Review: Brokerages Maintain Cautious Stance As US Challenges Loom
Dr. Reddy's' US sales continued to struggle due to inventory adjustments and pricing pressures on key products, Citi said.
Dr Reddy's Q2 performance sees revenue boost, but challenges persist
Dr Reddy’s Laboratories posted a mixed performance in Q2FY25, reporting record revenue of Rs 8,038.2 crore, marking a strong ...
cnbctv181h
Dr. Reddy's analysts remain cautious citing lack of near-term catalysts post Q2
Shares of Dr. Reddy's Laboratories Ltd. will be closely watched in Wednesday's trading as its revenue for the September ...
ndtvprofit36m
Dr. Reddy’s Q2 Results Review - Performance Inline With Expectations; Upgrade To 'Hold': Systematix
The brokerage expects the new business avenues to take a few years before they start contributing profitably to the ...
Dr Reddy’s clocks 16.51% increase in Q2 revenues
New Delhi: Pharma major Dr Reddy’s Laboratories (DRL ... Its total operating expenses grew 34.3 per cent to Rs3,021.8 ...
Dr Reddy’s Q2 profits decline 9%, revenue grows 17%
Pharma major Dr Reddy’s Laboratories’ net profit declined 9 per cent at ₹1,341 crore in the second quarter ended ...
cnbctv186h
Healthcare major Dr Reddy's Q2 net profit falls, revenue gains momentum
Healthcare major Dr Reddy's Laboratories reported a 15% decline in its consolidated net profit, totalling ₹1,255 crore ...
DRL Q2 net falls 15% despite revenue surge
HYDERABAD: Pharma major Dr Reddy's Laboratories on Tuesday reported a 15% drop in ... Consolidated net profit for Q2 ...